Immunologic profiling demonstrates serum IgE levels in cancer patients with cutaneous adverse events, highlighting polarized actionable immune pathways.
Supplementary Figure S3. Serum IgE levels in patients with cancer experiencing checkpoint inhibitor induced immune-related cutaneous adverse events (ircAE).
No takes yet. Share an insight, caveat, or question.
Lacouture et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: